[go: up one dir, main page]

WO2013061112A1 - Utilisation de modulateurs de egfl7 afin de favoriser ou d'inhiber la migration de cellules immunitaires à travers l'endothélium vasculaire - Google Patents

Utilisation de modulateurs de egfl7 afin de favoriser ou d'inhiber la migration de cellules immunitaires à travers l'endothélium vasculaire Download PDF

Info

Publication number
WO2013061112A1
WO2013061112A1 PCT/IB2011/054742 IB2011054742W WO2013061112A1 WO 2013061112 A1 WO2013061112 A1 WO 2013061112A1 IB 2011054742 W IB2011054742 W IB 2011054742W WO 2013061112 A1 WO2013061112 A1 WO 2013061112A1
Authority
WO
WIPO (PCT)
Prior art keywords
egfl7
cells
tumor
tumors
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2011/054742
Other languages
English (en)
Inventor
Fabrice Soncin
Sébastien PINTE
Suzanne DELFORTRIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to PCT/IB2011/054742 priority Critical patent/WO2013061112A1/fr
Publication of WO2013061112A1 publication Critical patent/WO2013061112A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily

Definitions

  • the present invention relates to a method of modulating transmigration of immune cells across vascular epithelium. More particularly, the present invention addresses two different types of situations: conditions where an upregulation of immune cells extravasation is needed and conditions where a downregulation of leukocytes transendothelial migration is preferred.
  • the present invention is based on the demonstration that elevated levels of Egfl7 prevent the normal activation of vascular endothelium.
  • One of the essential functions of the endothelial cell lining is to maintain the essentially impermeable nature of the blood vessels controlling the passage of solutes and immune cells from the circulation to the tissues.
  • the transmigration of leukocytes through the endothelium is a normal process which, during inflammation, results in the infiltration of circulating cells from the blood stream into tissues.
  • Leukocyte migration across the endothelium is a complex multistep process involving tethering, rolling, firm adhesion and finally extravasation.
  • the underlying mechanisms that regulate these processes have been the basis for many recent studies.
  • leucocyte extravasation had been believed to occur through a paracellular route, which involves localized disruption of endothelial cell junctions.
  • a transcellular route has been described involving the passage through the endothelial cell body.
  • Leucocytes are also able to migrate through epithelium to monitor mucosal tissues and microenvironments.
  • a number of molecules are known to regulate transmigration of leucocytes through epithelial and endothelial layers.
  • extravasation involves at least E- and P-selectin, ICAM-1 (intracellular adhesion molecule 1), VCAM-1 (vascular cell adhesion molecule 1 ), PECAM/CD31 (platelet-endothelial cell adhesion molecule), CD99, VE-cadherin (vascular endothelial cadherin) and JAM (junctional adhesion molecule) proteins (Garrido-Urbani et al., 2008; Muller, 2009).
  • the traversal of immune cells across the endothelial barrier and into the tissue space is an integral component of an immune response induced by infection or injury. Some conditions are characterized by aberrant or otherwise unwanted endothelial transmigration.
  • circulating immune cells such as natural killer (NK) cells and CD8+ cytotoxic T-lymphocytes
  • IFNg interferon- ⁇
  • cytotoxic-based mechanisms Castermans and Griffioen, 2007; Herberman et al., 1975; Koebel et al., 2007; Shrikant and Mescher, 1999.
  • circulating immune cells In order to destroy tumor cells, circulating immune cells must first infiltrate the tumor mass.
  • the tumor blood vessel endothelium although imperfectly tight, actively protects tumor cells from the immune system through its barrier function.
  • Tumor escape from immunity may be achieved by preventing infiltration of effector immune cells (Wu et al., 1992) through the down-regulation of these endothelial adhesion molecules (Dirkx et al., 2003; Griffioen et al., 1996; Kuzu et al., 1993; Piali et al., 1995).
  • Egfl7 VE-statin
  • VE-statin a gene specifically expressed by blood vessel endothelial cells in normal organs during development and in the adult.
  • this specificity of expression is lost as Egfl7 has been detected in tumor cells themselves, in addition to endothelial cells.
  • Its expression levels correlate with a higher tumor grade in glioma (Huang et al., 2010) and colon cancer patients (Diaz et al., 2008), and with a poorer prognosis and higher metastatic score in hepatocarcinoma patients (Wu et al., 2009).
  • Egfl7 is an endogenous regulator of endothelial cell activation which, when expressed by tumor cells, inliibits the recruitment of immune cells, thereby protecting the tumor from the host immunity.
  • the present invention hence pertains to a modulator of Egfl7, for use as an agent for promoting or inhibiting migration of immune cells across vascular endothelium.
  • immunoblasts designate leukocytes, including lymphocytes, granulocytes (including neutrophils), and monocytes.
  • the present invention relates to the use of a modulator of Egfl7 for modulating the migration of lymphocytes across the epithelium, including the extravasation step.
  • modulator designates any molecule which upregulates or downregulates the activity of Egfl7. Such modulation may be achieved by any suitable means and includes:
  • Egfl7 Modulating absolute levels of the active or inactive forms of Egfl7 (for example increasing or decreasing Egfl7 concentrations) such that either more or less Egfl7 is available for interacting with its downstream targets.
  • This can be achieved by acting either at the transcription level (for example, by introducing a siRNA targeting the gene of Egfl7 to decrease its expression, or by introducing into a cell a nucleic acid molecule encoding Egfl7 or functional equivalent, derivative or analogue thereof in order to upregulate the capacity of said cell to express Egfl7, to increase its expression), at the translation level, or at the post-translational level (for example by modulating the half life of Egfl7 by any means such as modifying its ability to be ubiquitinated).
  • Egfl7 itself can also be performed to increase its concentration and hence, its activity.
  • the mouse Egfl7 protein sequence is available in the database Swiss-Prot (Genbank) under the reference Q9QXT5, whereas the human sequence is available, in the same database, under the reference Q9UHF1.
  • the sequences are also enclosed as SEQ ID No: 1 (mouse Egfl7) and SEQ ID No: 2 (human EGfl7).
  • Egfl7 Agonising or antagonising Egfl7 such that the functional effectiveness of any given Egfl7 molecule is either increased or decreased.
  • antagonists of Egfl7 activity which can be used to that purpose are competitors such as fragments of the protein, as well as antibodies, fragments of antibodies, aptamers and the like.
  • a modulator according to the present invention can be a proteinaceous or a non-proteinaceous molecule.
  • the proteinaceous molecules described above may be derived from any suitable source such as natural, recombinant or synthetic sources and include fusion proteins or molecules which have been identified following, for example, natural product screening.
  • the reference to non-proteinaceous molecules may be, for example, a reference to a nucleic acid molecule or it may be a molecule derived from natural sources, such as for example natural product screening, or may be a chemically synthesised molecule.
  • the present invention contemplates analogues of Egfl7 or small molecules capable of acting as agonists or antagonists.
  • Chemical agonists may not necessarily be derived from the Egfl7 protein, but may share certain conformational similarities. Alternatively, chemical agonists may be specifically designed to meet certain physiochemical properties. Antagonists may be any compound capable of blocking, inhibiting or otherwise preventing Egfl7 from carrying out its normal biological function.
  • Screening for the modulatory agents hereinbefore defined can be achieved by any one of several suitable methods including, but in no way limited to, contacting a cell comprising the Egfl7 gene or functional equivalent or derivative thereof with an agent and screening for the modulation of Egfl7 protein production or functional activity, modulation of the expression of a nucleic acid molecule encoding Egfl7 or modulation of the activity or expression of a downstream Egfl7 cellular target (such as ICAM-1). Detecting such modulation can be achieved utilising techniques such as Western blotting, electrophoretic mobility shift assays and/or the readout of reporters of Egfl7 activity.
  • the modulators which are used according to the present invention may take any suitable form.
  • proteinaceous agents may be glycosylated or unglycosylated, phosphorylated or dephosphorylated to various degrees and/or may contain a range of other molecules used, linked, bound or otherwise associated with the proteins such as amino acids, lipid, carbohydrates or other peptides, polypeptides or proteins.
  • the subject non-proteinaceous molecules may also take any suitable form. Both the proteinaceous and non-proteinaceous agents herein described may be linked, bound otherwise associated with any other proteinaceous or non-proteinaceous molecules.
  • said agent is associated with a molecule which increases its solubility, availability and/or half-life, and/or which permits its targeting to a localised region and/or its entry to a cell, and/or which provides it with a further activity, such as cytotoxicity.
  • the term "antagonist of Egfl7” will indifferently designate any molecule inhibiting Egfl7 expression or promoting its degradation, as recited in point (i) above, or any molecule antagonizing Egfl7 activity, such as those described in the above point (ii).
  • the term "agonist of Egfl7” will indifferently designate Egfl7 itself, any molecule promoting its expression or inhibiting its degradation, or any molecule agonizing its activity.
  • the method of the present invention contemplates the modulation of transendothelial cell migration in both in vitro and in vivo.
  • the preferred method is to treat an individual in vivo, it should nevertheless be understood that the method of the invention can be applied in an in vitro environment, for example to provide an in vitro model of leukocyte extravasation.
  • the modulator is an antagonist of Egfl7, which promotes migration of immune cells across vascular endothelium.
  • the antagonist of Egfl7 favors the migration of lymphocytes from the blood vessels to the perfused tissues, across the epithelium.
  • an antagonist of Egfl7 according to the present invention will advantageously be used as an agent for increasing tumor infiltration by immune cells, and in particular by lymphocytes, especially T lymphocytes, as well as NK cells and dendritic cells.
  • the antagonist of Egfl7 is used as an agent for preventing tumor escape from immunity.
  • Egfl7 not only represses tumor endothelium activation, but also decreases expression of Tie-2, thereby affecting endothelium integrity and increasing tumor vessel permeability to tumor cells.
  • inhibiting Egfl7 in tumors, especially in tumors which over-express it leads not only to a better infiltration of the tumor mass by immune cells, but also to a decreased migration of tumor cells into vascular vessels.
  • the present invention hence also pertains to an antagonist of Egfl7 for use as an agent for preventing tumor cells intravasation, in particular for preventing metastasis.
  • Another object of present invention is a method for the treatment of a solid tumor in a patient in need thereof, comprising a step of administrating to said patient an antagonist of Egfl7.
  • An antagonist of Egfl7, for use as an agent for treating a solid tumor is hence part of the present invention.
  • solid tumors which can be treated by this method comprise breast cancer, prostate cancer, colon cancer, rectal cancer, bladder cancer, lung cancer, melanoma, non-Hodgkin lymphoma, endometrial cancer, pancreatic cancer, kidney cancer, thyroid cancer, brain tumor and head and neck cancer.
  • the treatment will be mostly effective in tumors over-expressing Egfl7.
  • the method can comprise an initial step of measuring, for example from a biopsy of a tumor, the level of expression of Egfl7 in said tumor.
  • Treatment with an antagonist of Egfl7 according to the present invention will be decided if the tumor expresses Egfl7, especially if the expression level is higher than in normal controls (expression level in normal tissues or in the same organ of individuals without cancer).
  • patient includes humans, primates, livestock animals (e.g. sheep, pigs, cattle, horses, donkeys), laboratory test animals (e.g. mice, rabbits, rats, guinea pigs), companion animals (e.g. dogs, cats) and captive wild animals (e.g., foxes, kangaroos, deer).
  • livestock animals e.g. sheep, pigs, cattle, horses, donkeys
  • laboratory test animals e.g. mice, rabbits, rats, guinea pigs
  • companion animals e.g. dogs, cats
  • captive wild animals e.g., foxes, kangaroos, deer
  • the individual is human or a laboratory test animal.
  • the patient is a human.
  • the antagonist of Egfl7 is formulated for intravenous administration.
  • routes of administration include, but are not limited to, intratumoral, respiratory, intratracheal, nasopharyngeal, intraperitoneal, subcutaneous, intracranial, intradermal, intramuscular, intraoccular, intranasal, infusion, oral, rectal, and via an implant.
  • Viral vectors as well as encapsulated forms can advantageously be used.
  • the present invention can be combined with another antitumor or anti-cancer treatment.
  • it can be combined with anti-tumor immunotherapy, especially for treating tumors which over-express Egfl7.
  • the anti-tumor immunotherapy treatments which can be combined with Egfl7 antagonists according to the invention include stimulatory treatments with interleukins, as well as cellular or peptide- based cancer vaccines. The combination will lead to a far better efficiency of said antitumor vaccine, since the immune cells generated by said vaccine will more efficiently infiltrated the tumor mass.
  • Non-limitative examples of anti-tumor therapeutic vaccines which can be combined with Egfl7 antagonists according to the present invention are Sipuleucel-T (ProvengeTM, Dendreon Corporation), as well as the single-peptide-based vaccines disclosed in Table 1 below.
  • the Egfl7 antagonist according to the present invention is combined to chemotherapy and/or radiotherapy, especially those which target metastases.
  • Egfl7 antagonists Although the main indication of Egfl7 antagonists is the presence of a solid tumor and/or metastases, there may be different circumstances in which it is desirable to upregulate transendothelial cell migration, such as, for example, infections by a pathogen, especially by a bacterium, a fungus, a virus or a multicellular parasite.
  • the antagonist of Egfl7 used according to the present invention can be a fragment of Egfl7, possibly fused to another moiety.
  • Other molecules such as antibodies, fragments of antibodies, aptamers (all targeting Egfl7), as well as oligonucleotides inhibiting Egfl7 expression can be used according to the present invention.
  • anti-Egfl7 antibodies are disclosed in US 2009/0297512 Al, US 2010/0285009 Al, WO 2007/106915 A2 and WO 2005/1 17968 A2.
  • Expression vectors encoding an inactive fragment of Egfl7 or an antibody, fragment of antibody or aptamer targeting Egfl7 can also be used according to the present invention.
  • Such expression vectors, as well as viral vectors or transformed cells comprising them, are also considered as "Egfl7 antagonists" in the present text.
  • a pharmaceutical composition, comprising an inhibitor of Egfl7 as described above, is also part of the present invention.
  • Another aspect of the present invention pertains to the use of Egfl7 or agonists thereof, for inhibiting endothelium activation and/or migration of immune cells across vascular endothelium. This can be helpful for preventing and/or treating pathologies characterized by aberrant, unwanted or otherwise excessive cellular transendothelial cell migration in an individual. This is of particular significance in the context of conditions such as atheromas, rheumatoid arthritis and inflammatory bowel disease. This aspect of the present invention is also particularly advantageous in situations where isolation of a particular organ or area from the immune system is needed, for example in the context of grafts or auto-immune diseases such as Type I diabetes.
  • Egfl7 or an agonist thereof, for inhibiting migration of immune cells across vascular endothelium, is hence part of the present invention.
  • Egfl7 could be used to attenuate the endothelial injury which occurs during hypoxia/reoxygenation during transplantation (Badiwala et al., 2010). They also suggested that Egfl7 could attenuate endothelial injury and arteriopathy resulting from chronic cyclosporine treatment of grafted people (Badiwala et al., 201 1). However, these authors did not envision any effect of Egfl7 different from preventing tissue injury due to inflammation at the level of vascular endothelium. In particular, they did not envision to isolate the grafted organ from immune cells, to protect it from the host immune response.
  • Egfl 7 produced by tumor cells had an effect on tumor vascular vessels, by preventing their activation and thereby inhibiting transmigration of immune cells towards the tumor.
  • This effect which is negative in the case of tumors, could be beneficial in other circumstances, such as in the case of grafted organs.
  • grafted organs are naturally attacked by the host's immune system, including lymphocytes and NK cells. Except in rare cases such as grafts between homozygotic twins, this renders immunosuppressant treatments compulsory, in spite of all the adverse effects of such treatments.
  • the present invention also pertains to the use of Egfl7 or an agonist thereof, as an agent for protecting a graft against immune cells of the host, especially against lymphocytes.
  • a method for preventing graft rejection in an individual comprising a step of administering Egfl7 or an agonist thereof to said individual, is also part of the present invention.
  • Egfl7 or its agonist is preferentially administered locally, at the tumor site. This can be performed by any appropriate means, such as, for example, an injection pump continuously delivering Egfl7 in (or nearby) the grafted organ.
  • Egfl7 can be administered in soluble form, as well as in encapsulated form.
  • Egfl7 or an agonist thereof is used as an agent for protecting a graft against immune cells of the host, in combination with an immunosuppressant drug.
  • drugs which can be used in this context are azathioprine, ICAM-1 , corticosteroids such as dexamethasone, anti-inflammatory molecules, calcineurin inhibitors (cyclosporine, tacrolimus), mTOR inhibitors (Sirolimus, Everolimus and rapamycine analogs), mycophenolic acid, and anti-CD20 or anti-IL2-receptor antibodies.
  • Egfi7 or an agonist thereof as an agent for preventing or treating a chronic inflammatory disease, and/or an auto-immune disease in which the patient's own immune cells destroy a particular tissue or organ.
  • type-1 diabetes is due to the destruction of islets of Langherans, located in the pancreas, by T lymphocytes infiltrating these islets. This destruction could be prevented by locally providing Egfl7 or an agonist thereof, to inhibit T lymphocytes infiltration of said islets.
  • transplantation of islets of Langerhans is an emerging treatment procedure for patients with type 1 diabetes. However, the procedure is associated with massive tissue loss caused by the immune system.
  • the transplanted islets are transformed to express Egfl7 or an agonist thereof, or associated with cells expressing Egfl7 or agonist thereof.
  • Other examples of auto-immune diseases and chronic inflammatory diseases which can be treated or attenuated by Egfl7 or an agonist thereof according to the present invention include as lupus erythematosus, autoimmune thyroiditis, experimental allergic encephalomyelitis (EAE), multiple sclerosis, Reynaud's syndrome, rheumatoid arthritis, psoriasis etc.
  • Egfl7 or an agonist thereof can also be administered to a patient to prevent or suppress delayed-type hypersensitivity reactions.
  • the invention further includes the above-described methods for suppressing an inflammatory response of the specific defense system in which an immunosuppressive agent is additionally provided to the subject.
  • an immunosuppressive agent is additionally provided to the subject.
  • Such an agent is preferably provided at a dose lower (i.e. a "sub-optimal" dose) than that at which it would normally be required.
  • a sub-optimal dose is possible because of the combined effect of the agent of the present invention. Examples of suitable immunosuppressive agents are listed above.
  • Egfl7 and its agonists can prevent extravasation of leukocytes, they can prevent or attenuate non-specific inflammations.
  • Such inflammatory reactions are due to reactions of the "non-specific defense system" which are mediated by leukocytes incapable of immunological memory.
  • Such cells include granulocytes and macrophages.
  • inflammation is said to result from a response of the nonspecific defense system, if the inflammation is caused by, mediated by, or associated with a reaction of the non-specific defense system.
  • inflammation which result, at least in part, from a reaction of the non-specific defense system include inflammation associated with conditions, such as adult respiratory distress syndrome (ARDS) or multiple organ injury syndromes secondary to septicemia or trauma, reperfusion injury of myocardial or other tissues, acute glomerulonephritis, reactivearthritis, dermatoses with acute inflammatory components, acute purulent meningitis or other central nervous system inflammatory disorders, thermal injury, hemodialysis, leukapheresis, ulcerative colitis, Crohn's disease, necrotizing enterocolitis, granulocyte transfusion associated syndromes and cytokine-induced toxicity.
  • ARDS adult respiratory distress syndrome
  • multiple organ injury syndromes secondary to septicemia or trauma reperfusion injury of myocardial or other tissues
  • acute glomerulonephritis acute glomerulonephritis
  • reactivearthritis reactivearthritis
  • dermatoses with acute inflammatory components acute purulent meningitis or other central nervous system inflammatory disorders
  • Immune responses to therapeutic or diagnostic agents such as, for example, bovine insulin, interferon, tissue-type plasminogen activator or murine monoclonal antibodies substantially impair the therapeutic or diagnostic value of such agents, and can, in fact, cause diseases such as serum sickness.
  • therapeutic or diagnostic agents such as, for example, bovine insulin, interferon, tissue-type plasminogen activator or murine monoclonal antibodies
  • Egfl7 or agonists thereof would be administered in combination with the therapeutic or diagnostic agent.
  • the Egfl7 or agonist thereof prevents the recipient from recognizing the agent, and therefore prevents the recipient from initiating an immune response against it. The absence of such an immune response results in the ability of the patient to receive additional administrations of the therapeutic or diagnostic agent.
  • the agonist of Egfl7 according to the present invention can be delivered by any route and under any pharmacological form.
  • routes of administration include, but are not limited to, intravenous, intratumoral, respiratory, intratracheal, nasopharyngeal, intraperitoneal, subcutaneous, intracranial, intradermal, intramuscular, intraoccular, intranasal, infusion, oral, rectal, and via an implant.
  • Examples of pharmaceutical formulations for delivering Egfl7 or an agonist thereof include, but are not limited to, particles comprising an expression vector encoding Egfl7 or agonist thereof (such as viral vectors, naked DNA, DNA encapsulated in a liposome or in any other encapsulating means, etc.), proteins (possibly encapsulated, possibly coupled to another moiety), etc.
  • a further aspect of the present invention is a pharmaceutical composition comprising, as an active ingredient, an expression vector encoding Egfl7 or an agonist thereof.
  • Non-limitative examples of such compositions include viral vectors expressing Egfl7, transformed cells, for example transformed epithelial cells, over-expressing Egfl7, and organoids expressing Egfl7.
  • Egfl7 promotes tumor growth and metastasis.
  • Tumor sections were immunostained using a specific anti-Egfl7 antibody (brown) in order to visualize the higher levels of expression in 4T1-Egfl7 tumors, bar represents ⁇ .
  • 4T1-Ctrl (o) and 4T1-Egfl7 ( ⁇ ) cells were implanted into the mammary fat-pad of Balb/c mice at day 0 and growing tumors measured over time, insert, average final weights of 4T1-Ctrl and 4T1-Egfl7 tumors.
  • LLC-Ctrl (o) or LLC-Egfl7 ( ⁇ ) were injected in the skin of C57B1/6 mice and tumors measured at regular times after injection, insert, average weights of LLC-Ctrl and LLC-Egfl7 tumors after 25 days.
  • Data are representative of a set of 4 and 3 experiments performed in similar conditions using 4T1 and LLC1 models, respectively. *; p ⁇ 0.05.
  • FIG. 1 A. 4T1-Ctii (o) and 4T1-Egfl7 ( ⁇ ) cells were plated at 1 ,250 cells/cm 2 in culture dishes and counted every day. Insert: over-expression of Egfl7 in 4T1- Egfl7 cells assessed by SDS-PAGE analysis of cell extracts and Western-blotting using antibodies directed against Egfl7-HA (top) and actin (bottom).
  • C. 4T1-Ctrl and 4T1 -Egfl7 cells (250 cells/cm 2 ) were seeded at low density in 0.45% agar, and cultured for 14 days, colonies were individually counted.
  • D. LLC-Ctrl (o) and LLCEgfl7 ( ⁇ ) cells were plated at 2,500 cells/cm 2 in culture dishes and counted every day. Insert: over-expression of Egfl7 in LLC-Egfl7 cells assessed by SDS-PAGE analysis of cell extracts and Western-blotting using antibodies directed against Egfl7-HA (top) and actin (bottom).
  • LLC-Ctrl and LLC-Egfl7 cells (5x10 4 cells) were plated onto 8 ⁇ -pore diameter membranes (0.3 cm 2 , Falcon), allowed to migrate for 24h at 37°C, trypsinized and counted. Data are expressed as percentage of migrated cells over the added numbers of cells counted in both chambers.
  • F. LLC-Ctrl and LLC-Egfl7 cells (250 cells/cm ) were seeded at low density in 0.45% agar, and cultured for 10 days, colonies were individually counted. The numbers of colonies were evaluated using the ImageJ vl .42q software.
  • Figure 3 Increased necrosis, hypoxia, angiogenesis, and permeability in 4T1-Egfl7 tumors.
  • 4T1-Ctrl and 4T1-Egfl7 tumor sections were stained with hematoxylin/eosin and necrosis identified as unstained areas, bars represent 1mm, right, necrotic areas were quantified as a percentage of total tumor area in the 4T1 and the LLC1 models,.
  • B. 4T1-Ctrl and 4T1-Egfl7 tumors were analyzed for hypoxia in 15 non- overlapping sections of 4T1 -Ctrl and 4T1-Egfl7 tumors.
  • D. Mice bearing 4T1-Ctrl or 4T1-Egfl7 tumors were injected with Lycopersicon esculentum-FYTC lectin and Dextran-Texas Red. Tumors were dissected and analyzed by fluorescent microscopy.
  • Red staining outside FITC-stained vessels indicates blood leakage, bar represents 100 ⁇ . Histogram on the right indicates the mean percentage of leaky vessels counted in 25 independent 0.15mm 2 fields of 4T1-Ctrl and 4T1 -Egfl7 tumors. *; p ⁇ 0.05.
  • Egfl7 prevents the infiltration of immune cells into 4T1- Egfl7 tumors.
  • CD3s + cells remained in the vessel lumens of 4T1-Egfl7 tumors (right, arrows), bar represents ⁇ ⁇ . right, average numbers of infiltrated CD3s + cells (outside of blood vessels) counted in 30 independent 0.15mm fields.
  • C Average numbers of cells positive for the indicated molecule counted within the tumor masses in 25 independent 0.15mm 2 fields. Data are representative of 2 experiments performed in similar conditions. **; p ⁇ 0.0l , * * * ; / ⁇ .001
  • FIG. 6 Immunostainings of 4T1-Ctrl (left) and 4T1-Egfl7 (right) tumor sections with the T-lymphocyte markers CD4 (A, red) and CD8 (B, red), B- lymphocyte marker CD 19 (C, confocal microscopy, red), macrophage marker CD68 (D, red), natural killer cells marker NKp46 (E, brown) and dendritic cell marker CDl l c (F, confocal microscopy, red) antibodies and DAPI (blue) counterstaining illustrate the depletion of immune cells within the 4T1-Egfl7 tumors. Data are representative of 2 experiments performed in similar conditions.
  • FIG. 7 Spleens of Balb/c animals bearing 4T1-Ctrl (white bars) and 4T1-Egfl7 tumors (black bars) were analyzed by flow cytometry for measuring the proportion of T-lymphocytes (CD3e, TCR, CD4, CD8), B-lymphocytes (CD19), and Natural Killer cells (NKp46).
  • T-lymphocytes CD3e, TCR, CD4, CD8
  • B-lymphocytes CD19
  • Natural Killer cells NKp46
  • FITC-conjugated monoclonal Abs against mouse CD4, CD8, CD45, PE-conjugated anti-CD4, -CD45, -NKP46, APC- conjugated anti-CD3, -CD19, purified anti-CD16/32, PE-Cy7 conjugated anti-CD8, and isotype controls were from BD Pharmingen, 7-AAD was from eBioscience. Spleens were harvested and mechanically homogenized. After washes, red blood cells were removed with lysis buffer (Sigma) and spleen cells counted using Trypan blue (Sigma).
  • FIG. 8 Egfl7 has no effects in the absence of a functional immune system.
  • FIG. 9 Primary aortic smooth muscle cells (5xl0 4 cells/well) were placed in the upper chamber of cell culture inserts (8 ⁇ pore size, Becton-Dickinson) in medium containing the indicated amounts of rEgfl7 and in the presence (+) or not (-) of 40 ng/ml porcine platelet-derived growth factor-BB (R&D). After 6hr, the cells that had migrated to the lower compartment were stained using hemalun and counted under a microscope. Full inhibition of cell migration was achieved in the presence of 50 ng/ml rVE-statin. B.
  • Dendritic cells (lxlO 5 cells/well) were incubated in the presence of LPS (1 ⁇ g/ml) and rEgfl7 (150 ng/ml) when indicated (+) for 24hr and the supernatants tested for the presence of IL12p40 by ELISA.
  • T-lymphocytes were incubated on anti-CD3 -coated wells (5x10 5 cells/well) in the presence of an anti- CD28 and in the presence of rEgfl7 (150 ng/ml) where indicated (+) for 5 days.
  • Cell proliferation was evaluated by incubating the cells with Alamar blue for 24hr and followed by a spectrophotometric dosage.
  • Egfl7 alters the tumor endothelium characteristics.
  • A. dendritic cells (lxl O 5 , left) were cultured for 24h in the presence of LPS and rEgfl7 where indicated (+) and IL6 was quantified in the supernatants.
  • NK cells (5x10 4 , middle) were incubated for 48h with IL12 and IL18 with and rEgfl7 where indicated (+) and IFNg was quantified in the supernatants.
  • Purified splenic T-lymphocytes (5xl 0 5 , right) were stimulated with plate-bound anti-CD3 and soluble anti-CD28 in the presence of rEgfl7 where indicated (+) for 48h and production of IFNg in the supernatants was quantified.
  • B. 4T1 -Ctrl and 4T1-Egfl7 tumors were sectioned and immunostained for ICAM- 1 (left, green) or VCAM-1 (right, red), and counterstained with DAPI (blue), bars represent ⁇ ⁇ .
  • Egfl7 prevents the adhesion of T-lymphocytes on endothelial cells.
  • CM-Ctrl 4T1 -Ctrl
  • CM-Egfl7 4T1 -Egfl7
  • FIG. 12 A. Analysis of the expression levels of Egfl7 transcripts in HUVEC transfected with a siRNA targeting Egfl7 (si-Egfl7) or control (si-Ctrl) as assessed by RT-qPCR, B. Transfection of HUVEC cells with si-Egfl7 increased icam- 1 expression; this effect was counteracted by the cotransfection of a siRNA targeting Icam-1. C. Transfection of HUVEC cells with si-Egfl7 increased Vcam-1 expression; this effect was counteracted by the co-transfection of a siRNA targeting Vcam-1. Expression levels of Icam-1 and Vcam-1 were measured by RT-qPCR in HUVEC cells. Levels are expressed at 2 "AACt taking si-Ctrl values as reference.
  • FIG. 13 High expression of Egfl7 correlates with low VCAM-1, ICAM-1 and IFNg in human tumors.
  • SBR II, RE+, RP+, HER2 0 The tumor tissue which expresses large amounts of Egfl7 within tumor cells (top left, *), shows low levels of ICAM-1 in adjacent blood vessels (bottom left, arrows).
  • Mouse mammary carcinoma 4T1 (ATCC CRL-2539), lung adenocarcinoma LLC1 (ATCC CRL-1642) and Jurkat (ATCC TIB- 152) cells were obtained from ATCC and were not further tested or authenticated. 4T1 and Jurkat cells were cultured in RPMI, 10% fetal bovine serum (FBS), lOOU/ml penicillin, 100 ⁇ g/ml streptomycin. LLC1 were cultured in DMEM, 10% FBS, lOOU/ml penicillin, 100 ⁇ g/ml streptomycin. Human primary umbilical vein endothelial cells (HUVEC, Lonza) were cultured in EGM-2 and used between passage 1 and 5.
  • FBS fetal bovine serum
  • LLC1 were cultured in DMEM, 10% FBS, lOOU/ml penicillin, 100 ⁇ g/ml streptomycin.
  • Human primary umbilical vein endothelial cells (HUVEC, Lonza) were cultured in E
  • Conditioned medium was produced by incubating 4T1-Ctrl or 4T1-Egfl7 cells (2xl04/cm 2 ) in EBM-2 (Lonza), 0.2% BSA for 24 hr. Medium was filtered (0.22 ⁇ ) before use. All cells were cultured in a humidified 95% air/5% C0 2 incubator at 37°C.
  • the mouse Egfl7 cDNA (Soncin et al., 2003) was cloned in frame with a C-terminal influenza hemagglutinin (HA)-coding sequence in the pMSCV plasmid (Clontech), allowing the production of retrovirus after transfection in HEKGP cells.
  • 4T1 and LLC1 cells were infected with control or Egfl7-coding viruses and whole cell populations were selected for puromycin resistance (4 ⁇ ⁇ ) for 7 days.
  • HUVEC were plated in 2cm 2 well-plates (25000 cells/cm 2 ) and transfected the next day with lOnM siRNA (Dharmacon) in Primefect siRNA reagent (Lonza) mixed with EGM-2. After 24hr, EGM-2 was added and cells cultured for 24hr or 48hr.
  • Tumor vessel perfusion Blood vessel leakage was assessed by injecting ⁇ ⁇ of PBS, 0.5mg/ml Lycopersicon esculentum lectin-FITC (Vector Laboratories) and 2.5mg/ml Dextran (70kD)-Texas Red (Molecular Probes) in the tail vein. Mice were euthanized after l Omin, and tumors were collected and processed for cryosection. Hypoxia was estimated after peritoneal injection of 0.15M NaCl, 60mg/kg pimonidazole-HCl (Hypoxyprobe, HPI). Mice were sacrificed after 30min, tumors were collected, proceeded for paraffin inclusion, and hypoxyprobe detected by immunohistochemistry.
  • Immunohistocliemistry Tumors were either fixed in 4% paraformaldehyde, embedded in paraffin and sectioned (7 ⁇ ) or frozen in OCT compound, sectioned at ⁇ ⁇ and post-fixed with 1% paraformaldehyde (5min). Immunostainings were performed using antibodies as listed in Table 2. For necrosis analysis, sections were stained with hematoxylin/eosin and necrotic areas identified as unstained regions. Apoptotic cells were visualized using the Terminal Transferase recombinant kit (Roche). Proliferating cells were detected by staining with a Ki67 antibody (Roche). For optical microscopy, sections were counterstained with hematoxylin.
  • Washed cells were incubated in DMEM, 0.2% FBS containing a rat anti- mouse CD16/CD32 (Fc-block, BD-Pharmingen, 553141, ⁇ g/10 6 cells) for lh at 4°C, then with anti-rat IgG coated magnetic beads (Dynabeads, Invitrogen) which had been incubated with a rat anti-mouse CD45 antibody (BD-Pharmingen, 550539) for 20min at 4°C.
  • CD45 " cells were collected and incubated with magnetic beads pre-incubated with a rat anti-mouse CD31/PECAM antibody (BD-Pharmingen, 553370) for 20 min at 4°C.
  • CD457CD31 + and CD457CD3 r cells were separated and lysed in TRIzol. Enrichment was evaluated by measuring the expression levels of CD31.
  • RNA were extracted and reverse transcribed using a high capacity cDNA reverse transcription kit (Life Technologies). Quantitative PCR (qPCR) were performed using TaqMan gene expression assays, reagents and conditions (Life Technologies).
  • Egfl7-HA, cleaved-caspase-3, and actin were detected using specific antibodies from Covance (HA.1 1 Clone 16B12, 1/1500), Cell signaling (9664S, 1/1000), and Santa Cruz Biotechnology (sc-1615, 1/1000), respectively. Chemiluminescence was measured using a Luminescent Image System (LAS3000, Fujifilm).
  • BM-DC bone marrow- derived cells
  • IMDM medium supplemented with 10% FBS and 1% of supernatant from GM-CSF-expressing J558-GM-CSF cells for 14 days.
  • Cells (10 5 cells/well) were stimulated or not with ⁇ g/ml LPS for 24h, in the presence or not of 150ng/ml mouse recombinant (r)Egfl7 (Caetano et al., 2006).
  • r mouse recombinant
  • IL6 and IL12p40 were quantified in the supernatants by ELISA (BD-Biosciences).
  • NK cell function mouse liver mononuclear cells were labeled with APC-conjugated anti-CD5 and PE-conjugated anti-NKl .
  • l mAbs CD57NK1.1 + cells were sorted using a FACSAria (BD Biosciences), cultured in RPMI, 5% FCS (10 4 cells/well) and stimulated with lOng/ml IL12 and lOng/ml IL18 in the presence or not of 150ng/ml rEgfl7 for 48h. IFNg production was analyzed in supernatants by ELISA (eBiosciences, Paris, France).
  • T-cells were purified from spleens by negative selection using a Dynal T-cell isolation kit (Life Technologies). T-cells (10 5 cells/well) were cultured in RPMI, 5% FCS and stimulated or not with plate-bound anti- CD3 ⁇ g/ml) and soluble anti-CD28 ( ⁇ g/ml), in the presence or not of 150ng/ml rEgfl7 for 48h. IFNg production was analyzed in supernatants by ELISA. Proliferation was assessed 96h later, using AlamarBlue (Life technologies).
  • Egfl7 promotes tumor growth and metastasis
  • mouse 4T1 breast cancer cells were infected with a retrovirus encoding the full length, HA- tagged, mouse Egfl7 (4T1-Egfl7) or with a control virus (4T1-Ctrl).
  • 4T1-Egfl7 cells formed tumors which showed a marked accumulation of Egfl7 (Fig. 1A, B).
  • Fig. 1A, B The tumors grew much faster in volume than 4T1-Ctrl tumors and, accordingly, the mean final weight of 4T1 -Egfl7 tumors was twice as high as that of 4T1-Ctrl tumors (Fig.
  • 4T1-Egfl7 tumors displayed larger necrotic areas than 4T1-Ctrl tumors (Fig. 3A) and a similar tendency was observed in LLC1 tumors.
  • Hypoxia was higher in 4T1-Egfl7 tumors than controls (Fig. 3B) whereas the apoptosis, cleaved caspase- 3 levels and Ki67 proliferation indexes were comparable between tumors (Fig. 4).
  • Microvessel density in angiogenic hot-spots was slightly increased in 4T1 -Egfl7 tumors when compared to controls, but was not significantly different between LLC1 tumors (Fig. 3C).
  • Egfl7 -expressing tumors are less infiltrated by immune cells.
  • mice carrying 4T1- Ctrl or 4T1-Egfl7 tumors showed no significant differences in the relative numbers of T- (CD3s + , TCR + ) and B-lymphocytes (CD 19 + ), or of NK cells (NKp46 + ), suggesting that the immune depletion was not systemic in mice carrying 4T1-Egfl7 tumors but was locally restricted to the tumor tissue (Fig. 7).
  • T-lymphocytes marker CD3s in LLC- Ctrl and LLC-Egfl7 tumors were assessed by SyBR-Green RT-qPCR using the primers 5'- aac acg tac ttg tac ctg aaa get c (SEQ ID No: 1) and 5 '-gat gat tat ggc tac tgc tgt ca (SEQ ID No: 2).
  • 4T1-Ctrl and 4T1-Egfl7 cells were injected in the mammary gland of immuno suppressed SCID-beige mice, which lack functional T-, B-, and NK cells.
  • 4T1-Ctrl tumors grew much faster and induced a higher rate of metastasis in SCID-beige mice when compared to Balb/c immunocompetent mice (Fig. 8), thus confirming the repressing effects of immune cells on tumor development.
  • Egfl7 represses leukocyte adhesion molecules in tumor endothelial cells
  • rEgfl7 which was active as an inhibitor of PDGF-BB-induced smooth muscle migration (Fig 9A, (Shioi et al., 2006; Soncin et al., 2003)), had no effect on the LPS-induced release of IL6 (Fig. 10A) and IL12p40 (Fig. 9B) by dendritic cells.
  • rEgfl7 did not affect IFNg production by NK cells stimulated with IL12 and IL18 and failed to modulate the anti-CD3/anti-CD28-stimulated production of IFNg by T- lymphocytes (Fig. 10A) as well as their proliferation (Fig. 9B).
  • Egfl7 could alter the recruitment of immune cells within the tumors.
  • Expression of cell adhesion molecules such as E- and P-selectins, ICAM-1 , VCAM-1 and CD31/PECAM by endothelial cells plays a crucial role in leukocyte rolling and adhesion before trans-endothelial migration (Muller, 2009). They detected high levels of expression of ICAM-1 and VCAM-1 in 4T1-Ctrl tumor blood vessels whereas expression was weak in 4T1-Egfl7 tumors (Fig. 10B). To confirm this, CD457CD31 + endothelial cells from tumors were isolated.
  • endothelial genes involved in promoting vessel integrity, maturation, and quiescence such as Tie-2 and PAI-1 were repressed by more than 80% in endothelial cells of 4T1-Egfl7 tumors whereas expression of uPA was increased in these cells (Fig. 10D).
  • Expression of D114 was strongly repressed, in agreement with the observed increased vascular density and hypoxia, but in apparent contradiction with the enhanced tumor development (Kuhnert et al., 201 1).
  • fit- 1 expression was strongly increased in 4T1-Egfl7 tumor endothelial cells and the expression levels of CD31/PECAM, P-selectin, VE-cadherin, eNOS, and of the integrin sub-units ⁇ , 3, ⁇ and ⁇ 3 were not modified (not shown).
  • Egfl7 directly regulates leukocyte adhesion on endothelial cells
  • Egfl7 directly affects the expression of leukocyte adhesion molecules by endothelial cells was studied in vitro using the Jurkat T-cell lymphoma model of immune cell adhesion on human primary HUVEC endothelial cells, a model known to depend on ICAM-1 and VCAM-1 (Chan et al., 2000).
  • Treatment of HUVEC with medium conditioned by 4T1 -Egfl7 cells reduced the number of T- lymphocytes adhering onto the endothelial monolayer by half when compared to cells incubated with a medium conditioned by 4T1-Ctrl cells (Fig. 1 1A). Repressing the endogenous egfl7 gene in endothelial cells using RNA interference (Fig.
  • FIG. 12 A doubled the number of T-lymphocytes adhering to HUVEC when compared to control (Fig. 1 IB). This correlated with a large increase in expression of E-selectin, Vcam-1 , and Icam-1 transcripts while expression of P-selectin and CD31/PECAM was not affected (Fig. 11C). Further, repressing either Icam-1 or Vcam-1 (Fig. 12B, C) in endothelial cells treated with a siRNA targeting Egfl7 reduced the effects of this latter siRNA on T-cell adhesion (Fig. 1 1D), suggesting that the repressing effects of Egfl7 on depend directly on the repression of Icam-1 and Vcam-1.
  • ICAM-1, VCAM-1 and IFNg were analyzed in a series of human breast carcinomas which were selected on the basis of their expression levels of Egfl7 in tumor cells (GLP, FS, personal communication). Within the same lesion, there was a 23% and 13% decrease in the numbers of blood vessels expressing ICAM-1 and VCAM-1 , respectively, when these vessels were in close vicinity to tumor cells expressing high levels of EgfI7, when compared to areas where expression of Egfl7 was low (peritumoral, Fig. 13 A, B). Furthermore, the levels of expression of IFNg were inversely correlated to the levels of expression of egfl7 measured in a series of human breast tumor samples (Fig. 13C).
  • Egfl7 is a natural repressor of endothelial cell activation. It inhibits the expression of endothelial adhesion molecules, and consequently reduces the adhesion of lymphocytes onto the endothelium. When placed in a tumor context, these effects result in an increased escape from immunity and a more rapid tumor growth.
  • Egfl7 could promote tumor growth and metastasis (Diaz et al., 2008; Huang et ah, 2010; Wu et al., 2009) but no experimental study had addressed the direct role of Egfl7 in tumor development.
  • the results obtained using two independent tumor models and mouse genetic backgrounds validate this initial hypothesis made on clinical observations.
  • over-expressing Egfl7 in experimental tumors allowed the inventors to understand its functions in more details.
  • Egfl7 is not an oncogene since it does not confer er se intrinsic proliferative or invasive properties to lung or breast tumor cells in vitro.
  • Egfl7 shows no effects on tumor growth when compared to controls, in the absence of a functional immune system.
  • the above data indicate that the effects of Egfl7 on tumor growth and metastasis are rather indirect: Egfl7 promotes tumor escape from immunity which, in turn, promotes tumor progression.
  • Egfl7 has no effect on the immune cells themselves. Indeed, it does not directly activate dendritic cells, NK cells or T-lymphocytes and does not affect their activation status upon stimulation.
  • the main effect of Egfl7 is to repress the tumor endothelium activation so that immune cells remain sequestered in the blood circulation, thus preventing their infiltration within the tumor mass.
  • Egfl7 favors tumor escape from immunity by downregulating the expression of endothelial adhesion molecules through mechanisms which are still elusive.
  • Egfl7 was recently reported to down- regulate the NF-KB pathway in human coronary artery endothelial cells after an ischemia/reoxygenation treatment (Badiwala et al., 2010). Based on this observation and the above results, it is thus possible that a direct repression of the NF-kB pathway by Egfl7 in endothelial cells contributes to the repression of ICAM-1 and, possibly, that of VCAM-1 and E-selectin.
  • Egfl7 increases blood vessel permeability and decreases expression of Tie-2 when compared to controls, suggesting that the endothelium integrity is altered in the presence of Egfl7. Since Egfl7 was shown to inhibit PDGF-BB-induced smooth muscle cell migration (Soncin et ah, 2003), it is likely that its expression prevents the recruitment of perivascular cells to newly formed tumor blood vessels, thus decreasing vascular tightness. Such a lack of vessel integrity is commonly observed in tumors (Jain, 2005) and is proposed to favor tumor spreading through metastasis (Mazzone et al., 2009; Rolny et al., 201 1).
  • Egfl7 In human breast tumor cells, the inventors observed that expression of Egfl7 corresponds to a local decrease in ICAM-1 and VCAM-1 expression in adjacent blood vessels, whereas more distant vessels are not affected. This suggests that Egfl7 has similar local effects on blood vessels in human tumors to those observed in experimental tumors in mice. The inverse correlation between the expression levels of Egfl7 in human tumors and those of IFNg further validates their hypothesis and suggests that Egfl7 produces an immune-deficient environment within human breast cancer tissues.
  • Epidermal growth factor-like domain 7 is a novel inhibitor of neutrophil adhesion to coronary artery endothelial cells injured by calcineurin inhibition. Circulation, 124, S I 97-203.
  • Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res, 63, 2322-2329.
  • Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
  • Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med, 181, 81 1-816.
  • Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé de modulation de la transmigration des cellules immunitaires à travers l'épithélium vasculaire. Plus particulièrement, la présente invention aborde deux types de situations. Dans des conditions où une régulation positive de l'extravasation des cellules immunitaires est nécessaire, par exemple dans les cancers, on utilise des antagonistes de EGFL7. Dans des conditions où une régulation négative de la migration transendothéliale des leucocytes est préférable, par exemple dans une inflammation pathologique, on utilise EGFL7 ou un agoniste de celui-ci.
PCT/IB2011/054742 2011-10-24 2011-10-24 Utilisation de modulateurs de egfl7 afin de favoriser ou d'inhiber la migration de cellules immunitaires à travers l'endothélium vasculaire Ceased WO2013061112A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2011/054742 WO2013061112A1 (fr) 2011-10-24 2011-10-24 Utilisation de modulateurs de egfl7 afin de favoriser ou d'inhiber la migration de cellules immunitaires à travers l'endothélium vasculaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2011/054742 WO2013061112A1 (fr) 2011-10-24 2011-10-24 Utilisation de modulateurs de egfl7 afin de favoriser ou d'inhiber la migration de cellules immunitaires à travers l'endothélium vasculaire

Publications (1)

Publication Number Publication Date
WO2013061112A1 true WO2013061112A1 (fr) 2013-05-02

Family

ID=44993635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/054742 Ceased WO2013061112A1 (fr) 2011-10-24 2011-10-24 Utilisation de modulateurs de egfl7 afin de favoriser ou d'inhiber la migration de cellules immunitaires à travers l'endothélium vasculaire

Country Status (1)

Country Link
WO (1) WO2013061112A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117968A2 (fr) 2004-04-14 2005-12-15 Genentech, Inc. Compositions et methodes destinees a la modulation du developpement vasculaire
WO2007106915A2 (fr) 2006-03-16 2007-09-20 Genentech, Inc. Anticorps à efgl 7 et leurs procédés d'utilisation
US20080113911A1 (en) 2006-07-17 2008-05-15 Calvin Jay Kuo Methods of modulating angiogenesis
WO2008128526A2 (fr) * 2007-04-20 2008-10-30 Johann Wolfgang Goethe-Universität Frankfurt am Main Utilisation d'egfl7 pour la modulation de cellules
US20100285009A1 (en) 2009-05-08 2010-11-11 Genentech, Inc. Humanized anti-egfl7 antibodies and methods using same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117968A2 (fr) 2004-04-14 2005-12-15 Genentech, Inc. Compositions et methodes destinees a la modulation du developpement vasculaire
US20090297512A1 (en) 2004-04-14 2009-12-03 Genentech, Inc. Compositions and methods for modulating vascular development
WO2007106915A2 (fr) 2006-03-16 2007-09-20 Genentech, Inc. Anticorps à efgl 7 et leurs procédés d'utilisation
US20080113911A1 (en) 2006-07-17 2008-05-15 Calvin Jay Kuo Methods of modulating angiogenesis
WO2008128526A2 (fr) * 2007-04-20 2008-10-30 Johann Wolfgang Goethe-Universität Frankfurt am Main Utilisation d'egfl7 pour la modulation de cellules
US20100285009A1 (en) 2009-05-08 2010-11-11 Genentech, Inc. Humanized anti-egfl7 antibodies and methods using same

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
ABRAMOFF, M.D.; MAGALHAES, P.J.; RAM, S.J.: "Image Processing with Image", J BIOPHOTONICS INTERNATIONAL, vol. 11, 2004, pages 36 - 42
ALITALO, K.; CARMELIET, P.: "Molecular mechanisms of lymphangiogenesis in health and disease", CANCER CELL, vol. 1, 2002, pages 219 - 227, XP002272726, DOI: doi:10.1016/S1535-6108(02)00051-X
ANITA E M DIRKX ET AL: "Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression.", CANCER RESEARCH, vol. 63, no. 9, 1 May 2003 (2003-05-01), pages 2322 - 2329, XP055032678, ISSN: 0008-5472 *
BADIWALA, M.V.; GUHA, D.; TUMIATI, L.; JOSEPH, J.; GHASHGHAI, A.; ROSS, H.J.; DELGADO, D.H.; RAO, V.: "Epidermal growth factor-like domain 7 is a novel inhibitor of neutrophil adhesion to coronary artery endothelial cells injured by calcineurin inhibition", CIRCULATION, vol. 124, 2011, pages 197 - 203
BADIWALA, M.V.; TUMIATI, L.C.; JOSEPH, J.M.; SHESHGIRI, R.; ROSS, H.J.; DELGADO, D.H.; RAO, V.: "Epidermal growth factor-like domain 7 suppresses intercellular adhesion molecule 1 expression in response to hypoxia/reoxygenation injury in human coronary artery endothelial cells", CIRCULATION, vol. 122, 2010, pages 156 - 161
CAETANO, B.; DROBECQ, H.; SONCIN, F.: "Expression and purification of recombinant vascular endothelial-statin", PROTEIN EXPR PURIF, vol. 46, 2006, pages 136 - 142, XP024908656, DOI: doi:10.1016/j.pep.2005.07.029
CASTERMANS, K.; GRIFFIOEN, A.W.: "Tumor blood vessels, a difficult hurdle for infiltrating leukocytes", BIOCHIM BIOPHYS ACTA, vol. 1776, 2007, pages 160 - 174, XP022338803, DOI: doi:10.1016/j.bbcan.2007.07.005
CHAN, J.R.; HYDUK, S.J.; CYBULSKY, M.I.: "Alpha 4 beta 1 integrin/VCAM-1 interaction activates alpha L beta 2 integrin-mediated adhesion to ICAM-1 in human T cells", J IMMUNOL, vol. 164, 2000, pages 746 - 753
CHUNG, A.S.; LEE, J.; FERRARA, N.: "Targeting the tumour vasculature: insights from physiological angiogenesis", NAT REV CANCER, vol. 10, 2010, pages 505 - 514
DIAZ, R.; SILVA, J.; GARCIA, J.M.; LORENZO, Y.; GARCIA, V.; PENA, C.; RODRIGUEZ, R.; MUNOZ, C.; GARCIA, F.; BONILLA, F.: "Deregulated expression of miR-106a predicts survival in human colon cancer patients", GENES CHROMOSOMES CANCER, vol. 47, 2008, pages 794 - 802, XP002629635, DOI: doi:10.1002/gcc.20580
DIRKX, A.E.; OUDE EGBRINK, M.G.; KUIJPERS, M.J.; VAN DER NIET, S.T.; HEIJNEN, V.V.; BOUMA-TER STEEGE, J.C.; WAGSTAFF, J.; GRIFFIOE: "Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression", CANCER RES, vol. 63, 2003, pages 2322 - 2329, XP055032678
EBOS, J.M.; LEE, C.R.; CRUZ-MUNOZ, W.; BJARNASON, G.A.; CHRISTENSEN, J.G.; KERBEL, R.S.: "Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis", CANCER CELL, vol. 15, 2009, pages 232 - 239
FAGIANI, E.; LORENTZ, P.; KOPFSTEIN, L.; CHRISTOFORI, G.: "Angiopoietin-1 and -2 Exert Antagonistic Functions in Tumor Angiogenesis, yet Both Induce Lymphangiogenesis", CANCER RES, vol. 71, 2011, pages 5717 - 5727
GARRIDO-URBANI, S.; BRADFIELD, P.F.; LEE, B.P.; IMHOF, B.A.: "Vascular and epithelial junctions: a barrier for leucocyte migration", BIOCHEM SOC TRANS, vol. 36, 2008, pages 203 - 211
GRIFFIOEN, A.W.; DAMEN, C.A.; MARTINOTTI, S.; BLIJHAM, G.H.; GROENEWEGEN, G.: "Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors", CANCER RES, vol. 56, 1996, pages 1111 - 1117
HASHIZUME, H.; BALUK, P.; MORIKAWA, S.; MCLEAN, J.W.; THURSTON, G.; ROBERGE, S.; JAIN, R.K.; MCDONALD, D.M.: "Openings between defective endothelial cells explain tumor vessel leakiness", AM JPATHOL, vol. 156, 2000, pages 1363 - 1380
HERBERMAN, R.B.; NUNN, M.E.; HOLDEN, H.T.; LAVRIN, D.H.: "Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells", INT J CANCER, vol. 16, 1975, pages 230 - 239
HUANG, C.H.; LI, X.J.; ZHOU, Y.Z.; LUO, Y.; LI, C.; YUAN, X.R.: "Expression and clinical significance of EGFL7 in malignant glioma", J CANCER RES CLIN ONCOL, vol. 136, 2010, pages 1737 - 1743, XP019849127
JAIN, R.K.: "Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy", SCIENCE, vol. 307, 2005, pages 58 - 62, XP002503618, DOI: doi:10.1126/SCIENCE.1104819
KOEBEL, C.M.; VERMI, W.; SWANN, J.B.; ZERAFA, N.; RODIG, S.J.; OLD, L.J.; SMYTH, M.J.; SCHREIBER, R.D: "Adaptive immunity maintains occult cancer in an equilibrium state", NATURE, vol. 450, 2007, pages 903 - 907
KUHNERT, F.; KIRSHNER, J.R.; THURSTON, G.: "D114-Notch signaling as a therapeutic target in tumor angiogenesis", VASC CELL, vol. 3, 2011, pages 20, XP021111368, DOI: doi:10.1186/2045-824X-3-20
KUZU, 1.; BICKNELL, R.; FLETCHER, C.D.; GATTER, K.C.: "Expression of adhesion molecules on the endothelium of normal tissue vessels and vascular tumors", LAB INVEST, vol. 69, 1993, pages 322 - 328
LELIEVRE, E.; HINEK, A.; LUPU, F.; BUQUET, C.; SONCIN, F.; MATTOT, V.: "VE-statin/egfl7 regulates vascular elastogenesis by interacting with lysyl oxidases", EMBO J, vol. 27, 2008, pages 1658 - 1670, XP055215304
M. V. BADIWALA ET AL: "Epidermal Growth Factor-Like Domain 7 Suppresses Intercellular Adhesion Molecule 1 Expression in Response to Hypoxia/Reoxygenation Injury in Human Coronary Artery Endothelial Cells", CIRCULATION, vol. 122, no. 11_suppl_1, 14 September 2010 (2010-09-14), pages S156 - S161, XP055032677, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.109.927715 *
MAZZONE, M.; DETTORI, D.; LEITE DE OLIVEIRA, R.; LOGES, S.; SCHMIDT, T.; JONCKX, B.; TIAN, Y.M.; LANAHAN, A.A.; POLLARD, P.; RUIZ: "Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization", CELL, vol. 136, 2009, pages 839 - 851
MULLER, W.A.: "Mechanisms of transendothelial migration of leukocytes", CIRC RES, vol. 105, 2009, pages 223 - 230
PAEZ-RIBES, M.; ALLEN, E.; HUDOCK, J.; TAKEDA, T.; OKUYAMA, H.; VINALS, F.; INOUE, M.; BERGERS, G.; HANAHAN, D.; CASANOVAS, O.: "Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis", CANCER CELL, vol. 15, 2009, pages 220 - 231
PIALI, L.; FICHTEL, A.; TERPE, H.J.; IMHOF, B.A.; GISLER, R.H.: "Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma", J EXP MED, vol. 181, 1995, pages 811 - 816, XP055032679, DOI: doi:10.1084/jem.181.2.811
ROLNY, C.; MAZZONE, M.; TUGUES, S.; LAOUI, D.; JOHANSSON, 1.; COULON, C.; SQUADRITO, M.L.; SEGURA, I.; LI, X.; KNEVELS, E.: "HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PIGF", CANCER CELL, vol. 19, 2011, pages 31 - 44
S. DELFORTRIE ET AL: "Egfl7 Promotes Tumor Escape from Immunity by Repressing Endothelial Cell Activation", CANCER RESEARCH, vol. 71, no. 23, 1 December 2011 (2011-12-01), pages 7176 - 7186, XP055032490, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-11-1301 *
SHIOI, K.; KOMIYA, A.; HATTORI, K.; HUANG, Y.; SANO, F.; MURAKAMI, T.; NAKAIGAWA, N.; KISHIDA, T.; KUBOTA, Y.; NAGASHIMA, Y.: "Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients", CLIN CANCER RES, vol. 12, 2006, pages 7339 - 7346
SHRIKANT, P.; MESCHER, M.F.: "Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness", J IMMUNOL, vol. 162, 1999, pages 2858 - 2866
SONCIN, F.; MATTOT, V.; LIONNETON, F.; SPRUYT, N.; LEPRETRE, F.; BEGUE, A.; STEHELIN, D.: "VE-statin, an endothelial repressor of smooth muscle cell migration", EMBO J, vol. 22, 2003, pages 5700 - 5711, XP002372368, DOI: doi:10.1093/emboj/cdg549
TOMAYKO, M.M.; REYNOLDS, C.P.: "Determination of subcutaneous tumor size in athymic (nude) mice", CANCER CHEMOTHER PHARMACAL, vol. 24, 1989, pages 148 - 154
WU, F.; YANG, L.Y.; LI, Y.F.; OU, D.P.; CHEN, D.P.; FAN, C.: "Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma", HEPATOLOGY, vol. 50, 2009, pages 1839 - 1850
WU, N.Z.; KLITZMAN, B.; DODGE, R.; DEWHIRST, M.W.: "Diminished leukocyte-endothelium interaction in tumor microvessels", CANCER RES, vol. 52, 1992, pages 4265 - 4268

Similar Documents

Publication Publication Date Title
Hou et al. Navigating CAR-T cells through the solid-tumour microenvironment
Luci et al. Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies
US12421495B2 (en) Compositions and methods for selective phagocytosis of human cancer cells
Fuertes et al. Leveraging NKG2D ligands in immuno-oncology
Ruth et al. CD6 is a target for cancer immunotherapy
Nausch et al. NKG2D ligands in tumor immunity
Akila et al. RETRACTED: CD163 and its expanding functional repertoire
US8142772B2 (en) Attack of tumor cells with missing, low or aberrant MHC expression by combining non MHC-restricted T-cells/NK-cells and MHC-restricted cells
US11207393B2 (en) Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
JP2022548523A (ja) 癌治療に向けた癌療法とサイトカイン制御療法との組み合わせ
Frishman-Levy et al. Central nervous system acute lymphoblastic leukemia: role of natural killer cells
KR20240007775A (ko) T 세포 수용체 및 이를 사용하는 면역 요법
KR20180021364A (ko) Car-t 세포의 간 동맥 주입
WO2007089945A2 (fr) Méthodes de traitement de maladies par ciblage du ilt3
US11788093B2 (en) Chimeric antigen receptor t-cells expressing interleukin-8 receptor
JP2021533822A (ja) Ｌｃｐ−１陽性がんを標的としたマイクロｒｎａベースの治療
MD3529262T2 (ro) Metode pentru promovarea răspunsului celulelor T
EP2413968B1 (fr) Produits thérapeutiques inhibiteurs de la sémaphorine 3c (sema3c), procédés et utilisations
Schepisi et al. Potential application of chimeric antigen receptor (CAR)-T cell therapy in renal cell tumors
EP2650013A1 (fr) Inhibiteurs du récepteur de produit terminal de glycosylation (RAGE) pour une utilisation dans le traitement du cancer induit par l'inflammation et/ou les lésions
Zhang et al. Targeting the cancer biomarker CD47: a review on the diverse mechanisms of the CD47 pathway in cancer treatment
Buras et al. Proinsulin-producing, hyperglycemia-induced adipose tissue macrophages underlie insulin resistance in high fat-fed diabetic mice
WO2013061112A1 (fr) Utilisation de modulateurs de egfl7 afin de favoriser ou d'inhiber la migration de cellules immunitaires à travers l'endothélium vasculaire
Won et al. A new triggering receptor expressed on myeloid cells (TREM) family member, TLT-6, is involved in activation and proliferation of macrophages
Habault et al. PAK1-Dependent Antitumor Effect of AAC-11‒Derived Peptides on Sézary Syndrome Malignant CD4+ T Lymphocytes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11784785

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11784785

Country of ref document: EP

Kind code of ref document: A1